## Derek O'hagan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11112219/publications.pdf

Version: 2024-02-01

18	1,975	18	18
papers	citations	h-index	g-index
18	18	18	2089
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Polylactide-co-glycolide (PLG) microparticles modify the immune response to DNA vaccination. Vaccine, 2008, 26, 753-761.	3.8	19
2	Nanoparticles and microparticles as vaccine-delivery systems. Expert Review of Vaccines, 2007, 6, 797-808.	4.4	232
3	A vaccination strategy to enhance mucosal and systemic antibody and T cell responses against influenza. Clinical Immunology, 2007, 123, 166-175.	3.2	23
4	Vaccines with the MF59 Adjuvant Do Not Stimulate Antibody Responses against Squalene. Vaccine Journal, 2006, 13, 1010-1013.	3.1	70
5	A modified process for preparing cationic polylactide-co-glycolide microparticles with adsorbed DNA. International Journal of Pharmaceutics, 2006, 327, 1-5.	5.2	23
6	A Practical Approach to the use of Nanoparticles for Vaccine Delivery. Journal of Pharmaceutical Sciences, 2006, 95, 2738-2750.	3.3	82
7	Polylactide-Co-Glycolide Microparticles with Surface Adsorbed Antigens as Vaccine Delivery Systems. Current Drug Delivery, 2006, 3, 115-120.	1.6	63
8	Characterization of Human Immunodeficiency Virus Gag-Specific Gamma Interferon-Expressing Cells following Protective Mucosal Immunization with Alphavirus Replicon Particles. Journal of Virology, 2005, 79, 7135-7145.	3.4	35
9	Mucosal adjuvants and delivery systems for proteinâ€, DNAâ€and RNAâ€based vaccines. Immunology and Cell Biology, 2004, 82, 617-627.	2.3	91
10	Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine, 2004, 22, 2489-2493.	3.8	154
11	Enhanced mucosal and systemic immune responses to Helicobacter pylori antigens through mucosal priming followed by systemic boosting immunizations. Immunology, 2003, 110, 86-94.	4.4	57
12	Induction of Broad and Potent Anti-Human Immunodeficiency Virus Immune Responses in Rhesus Macaques by Priming with a DNA Vaccine and Boosting with Protein-Adsorbed Polylactide Coglycolide Microparticles. Journal of Virology, 2003, 77, 6087-6092.	3.4	67
13	Human Immunodeficiency Virus Type 1 Gag–Specific Vaginal Immunity and Protection after Local Immunizations with Sindbis Virus–Based Replicon Particles. Journal of Infectious Diseases, 2001, 184, 1613-1616.	4.0	73
14	Induction of Potent Immune Responses by Cationic Microparticles with Adsorbed Human Immunodeficiency Virus DNA Vaccines. Journal of Virology, 2001, 75, 9037-9043.	3.4	186
15	Transcutaneous Immunization with Bacterial ADP-Ribosylating Exotoxins, Subunits, and Unrelated Adjuvants. Infection and Immunity, 2000, 68, 5306-5313.	2.2	135
16	Advances in vaccine adjuvants. Nature Biotechnology, 1999, 17, 1075-1081.	17.5	456
17	Mutants of <i>Escherichia coli </i> Heat-Labile Toxin Act as Effective Mucosal Adjuvants for Nasal Delivery of an Acellular Pertussis Vaccine: Differential Effects of the Nontoxic AB Complex and Enzyme Activity on Th1 and Th2 Cells. Infection and Immunity, 1999, 67, 6270-6280.	2.2	88
18	Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine, 1996, 14, 1523-1530.	3.8	121